52 Week Range
As of on the Virt-X ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Genmab: Partner For Ofatumumab Presents Positive Results From Phase III Asclepios I, II Studies
Novartis Says Data Shows Mayzent Can Help Patients With Secondary Progressive Sclerosis
Novartis Presents Anticipated Results From Phase III Trial Of B-Cell Therapy Ofatumumab
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Independent Non-Executive Chairman of the Board
Honorary Chairman of the Board
Daniel L. Vasella
Honorary Chairman of the Board
Chief Executive Officer, Member of the Executive Committee
Independent Non-Executive Vice Chairman of the Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.
* DATA SHOW THAT NEURONAL AND GLIAL FILAMENTS, BIOMARKERS OF DISEASE ACTIVITY, HAVE POTENTIAL TO SUPPORT DECISION MAKING IN MANAGEMENT OF MULTIPLE SCLEROSIS (MS) PATIENT
* NEW NOVARTIS DATA SHOW MAYZENT® CAN HELP PRESERVE MOBILITY FOR LONGER IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
* NOVARTIS DATA AT ECTRIMS TO HIGHLIGHT INNOVATIVE APPROACH TO REIMAGINING CARE FOR PEOPLE LIVING WITH MULTIPLE SCLEROSIS (MS)
Novartis <NOVN.S> Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity.
Novartis Chief Executive Vas Narasimhan promised to inform U.S. regulators quickly if credible questions emerge internally over data integrity, he told investors on Monday, following data manipulation allegations involving the Swiss drugmaker's $2.1 million gene therapy...
Novartis <NOVN.S> has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.
Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.
* IFM THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE OPTION AGREEMENT FOR CGAS/STING-FOCUSED SUBSIDIARY, IFM DUE
Novartis <NOVN.S> sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss newspaper reported on Wednesday, after the Swiss drugmaker held an event with German-language media on research and development...
Here are some of the main factors that may affect Swiss stocks on Wednesday:
Novartis AG's gene therapy for blindness, Luxturna, is recommended for use on England's public health service, the country's healthcare cost-effectiveness watchdog NICE said on Tuesday.
Swiss drugmakers Novartis <NOVN.S> and Lonza <LONN.S> separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.
Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus.
Novartis on Friday announced positive study results for its prospective multiple sclerosis drug ofatumumab that the Swiss drugmaker hopes will pose a stiff challenge to Roche's medicine Ocrevus in a highly competitive market.
* AGREES TO TERMINATE 85 BILLION WON ($70.09 million) WORTH CONTRACT WITH NOVARTIS' UNIT IN SOUTHEAST ASIA Source text for Eikon: https://bit.ly/2NwTDEF Further company coverage: ($1 = 1,212.6600 won)
* Shares fall as much as 2.9% (Recasts first paragraph, adds comment from analyst)
Novartis <NOVN.S> plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.
An unnamed Novartis executive sold 925,400 Swiss francs (778,665 pounds) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.